Stanford University Cancer Center, Stanford, California, USA.
Br J Haematol. 2023 May;201(3):381-382. doi: 10.1111/bjh.18649. Epub 2023 Jan 23.
Classification of the heterogeneous spectrum of myelodysplastic syndromes (MDS) requires both morphologic and molecular analysis to effectively subgroup patients. The paper by Zhang et al demonstrated the positive impact of combining the International Consensus Consortium (ICC) morphologic approach with prior clinical (IPSS-R) and mutational (IPSS-M) categorization to provide useful clinical evaluation of MDS patients. Commentary on: Zhang et al. Impact of the International Consensus Classification of Myelodysplastic Syndromes. Br J Haematol 2022 (Online ahead of print). doi: 10.1111/bjh.18628.
骨髓增生异常综合征（MDS）异质性谱的分类需要形态学和分子分析相结合，以有效地对患者进行亚组分类。Zhang 等人的论文表明，将国际共识联合会（ICC）形态学方法与先前的临床（IPSS-R）和突变（IPSS-M）分类相结合，对 MDS 患者进行有用的临床评估具有积极影响。评论：Zhang 等人。骨髓增生异常综合征国际共识分类的影响。英国血液学杂志 2022 年（在线提前印刷）。doi：10.1111/bjh.18628。
Zotero 插件